Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

被引：63

作者：

Abenavoli, Ludovico ^{[1
]}

Falalyeyeva, Tetyana ^{[2
]}

Boccuto, Luigi ^{[3
,4
]}

Tsyryuk, Olena ^{[2
]}

Kobyliak, Nazarii ^{[5
]}

机构：

[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, I-8810 Catanzaro, Italy

[2] Taras Shevchenko Natl Univ Kyiv, Sch Med, Volodymyrska St 64-13, UA-01601 Kiev, Ukraine

[3] Greenwood Genet Ctr, Greenwood, SC 29646 USA

[4] Clemson Univ, Sch Hlth Res, Clemson, SC 29646 USA

[5] Bogomolets Natl Med Univ, Dept Endocrinol, Pushkinska 22a, UA-01610 Kiev, Ukraine

来源：

PHARMACEUTICALS | 2018年 / 11卷 / 04期

关键词：

nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; fibrosis; obeticholic acid; farnesoid X receptor; metabolism; FARNESOID-X-RECEPTOR; HEPATIC STEATOSIS; AGONIST; FXR; HYPERTENSION; INFLAMMATION; ELAFIBRANOR; PROBIOTICS; REDUCTION; PROTECTS;

D O I：

10.3390/ph11040104

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.

引用

页数：10

共 53 条

[21] Fructose and sugar: A major mediator of non-alcoholic fatty liver disease [J].

Jensen, Thomas ;

Abdelmalek, Manal F. ;

Sullivan, Shelby ;

Nadeau, Kristen J. ;

Green, Melanie ;

Roncal, Carlos ;

Nakagawa, Takahiko ;

Kuwabara, Masanari ;

Sato, Yuka ;

Kang, Duk-Hee ;

Tolan, Dean R. ;

Sanchez-Lozada, Laura G. ;

Rosen, Hugo R. ;

Lanaspa, Miguel A. ;

Diehl, Anna Mae ;

Johnson, Richard J. .

JOURNAL OF HEPATOLOGY, 2018, 68 (05) :1063-1075

[22] New developments in the treatment of primary biliary cholangitis - role of obeticholic acid [J].

Jhaveri, Manan A. ;

Kowdley, Kris V. .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 :1053-1060

[23] Probiotics and nutraceuticals as a new frontier in obesity prevention and management [J].

Kobyliak, N. ;

Falalyeyeva, T. ;

Boyko, N. ;

Tsyryuk, O. ;

Beregova, T. ;

Ostapchenko, L. .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 141 :190-199

[24] Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study [J].

Kobyliak, Nazarii ;

Abenavoli, Ludovico ;

Falalyeyeva, Tetyana ;

Mykhalchyshyn, Galyna ;

Boccuto, Luigi ;

Kononenko, Liudmyla ;

Kyriienko, Dmytro ;

Komisarenko, Iuliia ;

Dynnyk, Oleg .

MINERVA MEDICA, 2018, 109 (06) :418-428

[25] A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial [J].

Kobyliak, Nazarii ;

Abenavoli, Ludovico ;

Mykhalchyshyn, Galyna ;

Kononenko, Liudmyla ;

Boccuto, Luigi ;

Kyriienko, Dmytro ;

Dynnyk, Oleg .

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2018, 27 (01) :41-49

[26] Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease [J].

Kobyliak, Nazarii ;

Abenavoli, Ludovico ;

Falalyeyeva, Tetyana ;

Beregova, Tetyana .

ANNALS OF HEPATOLOGY, 2018, 17 (01) :153-161

[27] Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition [J].

Kobyliak, Nazarii ;

Falalyeyeva, Tetyana ;

Beregova, Tetyana ;

Spivak, Mykola .

ENDOKRYNOLOGIA POLSKA, 2017, 68 (06) :659-+

[28] Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity [J].

Kobyliak, Nazarii ;

Falalyeyeva, Tetyana ;

Bodnar, Petro ;

Beregova, Tetyana .

PROBIOTICS AND ANTIMICROBIAL PROTEINS, 2017, 9 (02) :123-130

[29] Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention [J].

Kobyliak, Nazarii ;

Falalyeyeva, Tetyana ;

Virchenko, Oleksandr ;

Mykhalchyshyn, Galyna ;

Bodnar, Petro ;

Spivak, Mykola ;

Yankovsky, Dmytro ;

Beregova, Tetyana ;

Ostapchenko, Lyudmyla .

BMC GASTROENTEROLOGY, 2016, 16

[30] The Role of Liver Biopsy to Assess Non-Alcoholic Fatty Liver Disease [J].

Kobyliak, Nazarii ;

Abenavoli, Ludovico .

REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (03) :159-169

← 1 2 3 4 5 6 →